News Posts List
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
09/03/2014
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in vitro
09/03/2014
Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer therapy.
New agents and new targets for renal cell carcinoma
08/29/2014
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC).
EDAP Highlights HIFU Expertise at 7th International Symposium
08/27/2014
Focal Therapy and Imaging in Prostate and Kidney Cancer
Want to help researchers by clicking your mouse?
08/26/2014
You can be a part of an important study being conducted by researchers at Northwestern University.
Research Grant in Kidney Cancer - Young Investigator Award
08/26/2014
The application deadline is September 25, 2014. Recipients will be announced in April 2015.
Ten Questions to Ask Your Doctor After a Cancer Diagnosis
08/26/2014
Dr. Bavesh Balar is a board-certified hematologist and oncologist on staff at CentraState Medical Center in Freehold, N.J.
AUDIO: A call for clinical cancer trials to be more efficient
08/26/2014
Professor Dilts has some suggestions how to improve the situation.
Sequence of rare kidney cancer reveals unique alterations involving telomerase
08/25/2014
Clues about genetic alterations that may contribute to a rare form of kidney cancer have been discovered...
Diabetes mellitus is independently associated with an increased risk of mortality among clear cell renal cell carcinoma patients
08/23/2014
Conflicting data exist regarding the interaction of diabetes mellitus (DM) with outcomes for patients with renal cell carcinoma (RCC).
News Feed